- Home
- JYNT vs IPHA Comparison
JYNT vs IPHA Comparison
Compare JYNT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- IPHA
- Stock Information
- Founded
- JYNT 2010
- IPHA 1999
- Country
- JYNT United States
- IPHA France
- Employees
- JYNT N/A
- IPHA N/A
- Industry
- JYNT Multi-Sector Companies
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- IPHA Health Care
- Exchange
- JYNT Nasdaq
- IPHA Nasdaq
- Market Cap
- JYNT 163.0M
- IPHA 187.0M
- IPO Year
- JYNT 2014
- IPHA 2019
- Fundamental
- Price
- JYNT $11.46
- IPHA $2.33
- Analyst Decision
- JYNT Strong Buy
- IPHA Strong Buy
- Analyst Count
- JYNT 2
- IPHA 1
- Target Price
- JYNT $18.00
- IPHA $11.50
- AVG Volume (30 Days)
- JYNT 31.2K
- IPHA 5.8K
- Earning Date
- JYNT 08-08-2024
- IPHA 09-12-2024
- Dividend Yield
- JYNT N/A
- IPHA N/A
- EPS Growth
- JYNT N/A
- IPHA N/A
- EPS
- JYNT N/A
- IPHA N/A
- Revenue
- JYNT $120,071,078.00
- IPHA $68,134,188.00
- Revenue This Year
- JYNT $0.70
- IPHA N/A
- Revenue Next Year
- JYNT N/A
- IPHA $105.84
- P/E Ratio
- JYNT N/A
- IPHA N/A
- Revenue Growth
- JYNT 7.46
- IPHA 6.88
- 52 Week Low
- JYNT $7.31
- IPHA $1.81
- 52 Week High
- JYNT $17.82
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- JYNT 46.27
- IPHA 54.07
- Support Level
- JYNT $10.75
- IPHA $2.22
- Resistance Level
- JYNT $11.46
- IPHA $2.41
- Average True Range (ATR)
- JYNT 0.31
- IPHA 0.14
- MACD
- JYNT 0.09
- IPHA 0.00
- Stochastic Oscillator
- JYNT 72.45
- IPHA 67.65
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.